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Abstract: Vascular calcification is highly prevalent in patients with coronary artery 
disease and, when present, is associated with major adverse cardiovascular events, 
including an increased risk of cardiovascular mortality. The pathogenesis of vascular 
calcification is complex and is now recognized to recapitulate skeletal bone formation. 
Vascular smooth muscle cells (SMC) play an integral role in this process by undergoing 
transdifferentiation to osteoblast-like cells, elaborating calcifying matrix vesicles and 
secreting factors that diminish the activity of osteoclast-like cells with mineral resorbing 
capacity. Recent advances have identified microRNAs (miRs) as key regulators of this 
process by directing the complex genetic reprogramming of SMCs and the functional 
responses of other relevant cell types relevant for vascular calcification. This review will 
detail SMC and bone biology as it relates to vascular calcification and relate what is known 
to date regarding the regulatory role of miRs in SMC-mediated vascular calcification. 
Keywords: microRNAs; matrix vesicles; osteoclasts; vascular smooth muscle cells; 
vascular calcification 
 
1. Introduction 
Vascular calcification is a highly prevalent phenotype that is identified frequently in patients with 
atherosclerosis, diabetes mellitus and chronic kidney disease (CKD). Community-based studies have 
also demonstrated that vascular calcification occurs as a consequence of aging with detectable 
coronary artery calcification present in ≥90% of men and ≥67% of women who are age 70 years or 
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older [1,2]. In other population-based studies, the finding of ectopic vascular calcification has been 
associated with major adverse cardiovascular events. One meta-analysis that included 218,080 patients 
that were followed for ~10 years found that the presence of vascular calcification was associated with 
an odds ratio for cardiovascular mortality of 3.94 (95% CI: 2.39–6.50) [3]. 
Vascular (coronary artery) calcification is a well-accepted marker of increased cardiovascular risk, 
and compared to individuals with a coronary artery calcium score (CAC) = 0, those with a score >300 
have a 10-fold increased risk for any cardiovascular event [4,5]. Moreover, CAC scores have been 
shown to be better predictors of risk than other markers, such as C-reactive protein, family history and 
the ankle-brachial index [6]. The addition of the CAC score to risk prediction models improves the 
classification of patients at risk for adverse cardiovascular events, and pooled data revealed that the 
annual rate of cardiac death or myocardial infarction was 0.4%, 1.3% or 2.4%, respectively, with each 
increasing tertile of CAC (<100, 100–399 and >400) [7]. These data also revealed that individuals with 
intermediate risk scores and high CAC scores (>400) had a coronary heart disease equivalent risk with 
up to a 20% event rate over 10 years [8]. Studies have evaluated the added information gained by 
nuclear stress testing with myocardial perfusion imaging. In one study of 462 patients that underwent 
coronary CT scan and single-photon emission computed tomography (SPECT)-myocardial perfusion 
imaging (MPI), those individuals that were found to have matched areas of calcification and perfusion 
defects had worse survival over a mean of 34.5 ± 13.0 months follow-up [9]. Coronary artery 
calcification was also shown to provide stepwise incremental information regarding future adverse 
events in patients with or without ischemia detected by positron emission tomography perfusion 
imaging [10]. Currently, American Heart Association guidelines suggest that cardiac CT to identify 
vascular calcification may be beneficial for individuals with an intermediate Framingham Risk Score [8]. 
The aforementioned studies all support the concept that CAC is linked to increased cardiovascular 
risk; however, to date, there are no data demonstrating that CAC is causal for adverse cardiovascular 
events. 
Vascular calcification is typically localized to neointimal plaques that encroach upon the vessel 
lumen in atherosclerotic vessels, where it is present in a punctate or patchy pattern [11]. Vascular 
calcification also occurs in the medial layer of the vessel, which is known as Monckeberg’s medial 
sclerosis, where mineralization can be widespread, with a predilection for the vascular smooth muscle 
cells (SMC), the elastic lamellae and the extracellular matrix [12]. 
The pathogenesis of vascular calcification is a complex multifactorial process that has been 
attributed to inflammation, disorders of metabolism and genetic causes. Vascular medial calcification, 
in particular, has been shown to occur in diseases, such as diabetes mellitus and chronic kidney 
disease, which are associated with abnormal metabolic profiles. Calcification of the media has also 
been linked to a number of monogenetic disorders (e.g., polymorphisms in the genes MGP, OPG, 
ENPP1 and NTE5) that mainly affect calcium-phosphate homeostasis [13,14]. The complexity of 
vascular medial calcification is underscored further by the fact that this is likely a multicellular process 
with the involvement of osteoprogenitor cells, inflammatory cells and vascular cells that together 
recapitulate the cellular processes related to skeletal bone formation and remodeling [13–16]. 
One component of the vascular calcification process involves the reprogramming and 
transdifferentiation of SMC to osteoblast-like cells. These osteoblast-like SMCs generate and release 
calcifying matrix vesicles that are another essential factor involved in vascular calcification [17]. Cells 2014, 3   
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Concomitant loss of circulating inhibitors of vascular calcification; increased cellular stress, such as 
oxidant stress, endoplasmic reticulum stress or DNA damage response signaling, apoptosis and cell 
death and disorders of calcium-phosphate homeostasis all contribute to creating the milieu that favors 
mineral deposition in the vessel wall and frank calcification. 
As the process of vascular calcification is tightly regulated and involves genetic reprogramming of 
SMC and dynamic regulation of pro-calcifying peptides and inhibitors, it is not surprising that there is 
accumulating evidence to support an integral role for microRNAs (miRs) in this process. Emerging 
data has established that miRs regulate several key checkpoints in the cellular processes involved in 
vascular calcification. This review will briefly summarize the cellular and molecular mechanisms 
underlying vascular calcification and present evidence supporting the role of miRs in regulating 
integral processes for vessel wall mineralization. 
2. Mechanisms of Bone Formation 
Vascular calcification is now recognized to occur as a result of the same processes involved in bone 
formation. Bone forming osteoblasts are derived from mesenchymal cells that progressively differentiate 
into proliferating preosteoblasts, osteoblasts capable of synthesizing bone matrix, and that eventually 
turn into osteocytes that are resident in mature bone. Runx2 is a master osteoblast transcription factor 
and is recognized as the earliest osteoblastic marker [18]. Runx2 regulates the expression of osteocalcin, 
sclerostin, dentin matrix protein 1, vascular endothelial growth factor and the receptor activator of 
nuclear factor-kappaβ ligand (RANKL) [19]. The transcription factor, osterix, which is downstream 
from Runx2, is necessary for osteoblast differentiation [20]. Osterix regulates the expression of the 
extracellular matrix protein, bone sialoprotein, as well as the proteoglycans, osteomodulin, asporin and 
osteoglycin [21]. Bone morphogenetic proteins (BMPs), angiogenic factors and growth factors also 
regulate osteoblast differentiation, in part by activation of Wnt signaling [15,22]. Wnt proteins 
promote osteoblast differentiation by binding to the low-density lipoprotein receptor-related protein-5 
or -6 and one of the frizzled molecules to stabilize β-catenin and regulate transcription factor 
expression [22,23]. Canonical Wnt signaling favors osteoblast differentiation from mesenchymal cells 
at the expense of adipogenesis and is regulated by Runx2 and osterix [24,25]. 
Fully mature osteoblasts express type 1 collagen and alkaline phosphatase [26]. These mature cells 
also produce osteocalcin, osteopontin and osteonectin, which regulate matrix mineralization, as well as 
RANKL, which is necessary for osteoclast differentiation [27]. At the end of their lifespan, osteoblasts 
transform into osteocytes. Osteocytes are embedded into the mineralized bone matrix and express 
fibroblast growth factor-23 and sclerostin, which control phosphate metabolism and bone formation [27]. 
Another key feature of bone formation and remodeling involves osteoclasts. Osteoclast differentiation 
is regulated through the RANKL/RANK/osteoprotegerin signaling pathway. This pathway links bone 
forming osteoblasts, which synthesize RANKL, to osteoclast differentiation that occurs after RANKL 
binds to the membrane receptor RANK on osteoclast precursors [27]. Osteoclast differentiation by 
RANKL is inhibited by osteoprotegerin, which is a decoy receptor that binds RANKL to limit RANK 
activation and osteoclast differentiation [27]. Osteoprotegerin is also produced by osteoblasts [28]. 
During normal bone remodeling, bone resorption occurs concomitant with bone matrix elaboration 
and is matched to maintain bone density. This coupling of the two processes is suggested to occur as a Cells 2014, 3   
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result of growth factors and cytokines liberated during bone resorption. It also appears to involve 
signaling through sphingosine-1-phosphate, the transmembrane protein, ephrinB2, that is expressed on 
osteoblasts and the ephrin receptor B4 on osteoclasts [29]. Ephrin signaling by cell-cell contact 
stimulates osteoblast differentiation and represses osteoclast differentiation [29]. Conversely, 
sphingosine-1-phosphate, which is secreted by osteoclasts, leads to recruitment and differentiation of 
osteoblast progenitors. This shuts down bone resorption and initiates bone matrix elaboration [30]. 
A number of factors have been shown to be important for bone remodeling, including the BMPs, 
transcription factors Runx2 and osterix and Wnt signaling [31]. Other important factors include 
fibroblast growth factor-23 and klotho. Fibroblast growth factor-23 mediates renal phosphate excretion 
by inhibiting the sodium-phosphate transporters, NPT2a and NPT2c, to prevent reabsorption. Klotho 
was identified as a fibroblast growth factor-23 co-receptor that is required for these actions [32]. 
Emerging evidence indicates that there is an additional level of regulation that is mediated by small  
non-coding single-stranded RNAs or microRNAs (miRs) [33]. These ~22 nucleotide small RNAs are 
post-transcriptional regulators of gene expression that in disease states, such as vascular calcification, 
may regulate clusters of genes linked to disease pathogenesis. 
3. miRs That Regulate SMC Transdifferentiation 
The transdifferentiation of SMCs to osteoblast-like cells that elaborate bone matrix is a recognized 
contributor to vascular calcification [14,34]. These calcifying SMCs have enabled a genetic program 
that allows them to resemble osteoblasts and utilize the same bone forming mechanisms for in situ 
calcification in vessels [34]. miRs play an integral role in SMC transdifferentiation by regulating 
Runx2 and osterix expression in conjunction with other pertinent signaling pathways (Figure 1). 
Several studies have identified miRs that that are associated with calcification of SMCs in vitro, 
although these studies differ in the origin or vascular bed of SMCs studied, the pro-calcification 
conditions and the timing of analysis. In addition, many studies used a reductionist approach and 
examined only one miR and one target. Nonetheless, the totality of the studies indicates that there is 
redundancy in the system, with many miRs implicated in vascular calcification having the same target. 
For instance, miR-125b was the first miR to be associated with human coronary artery SMC 
calcification. After 21 days in osteogenic medium, miR-125b was decreased in these cells compared to 
controls. The transcription factor, osterix, was identified as a miR-125b target, and inhibition of miR-125 
was associated with increased Runx2 and osterix expression, as well as increased alkaline phosphatase 
activity and SMC calcification. In vivo, miR-125b was downregulated in calcified aortas from   
30-week-old apoE knockout mice. Interestingly, this study also reported that dicer and Drosha mRNA 
were downregulated in SMC under procalcifying conditions; however, protein levels were not 
examined, and it is not known if diminished expression of these processing enzymes had a global 
effect on other miRs [35]. Human aortic SMC, exposed to high phosphate conditions, demonstrated 
downregulation of miR-205 expression as early as three days after the initial exposure and by ~50% by 
10 days. This occurred prior to the increased expression of its targets, Smad1 and Runx2, and cell 
mineralization [36]. 
Other studies found that miRs that target Runx2, including miR-133 and miR-204, are 
downregulated in murine aorta SMCs, leading to calcification in vitro [37,38]. miR-204, which is Cells 2014, 3   
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encoded in the transient receptor potential cation channel subfamily M member 3 gene, was also shown 
to regulate in vivo calcification in a vitamin D3 (500,000 IU/kg SQ daily day 1–3) murine model of 
vascular calcification. In this model, aorta calcification was associated with an increase in vascular 
Runx2 expression. Mice treated with agomiR-204 (80 mg/kg) to increase miR-204 expression had 
significantly less calcification and decreased aorta Runx2 expression and no effect on bone density, 
thereby confirming that manipulating miR expression levels may have therapeutic effects for vascular 
calcification [38]. 
Figure 1. miRs regulate vascular medial calcification. miRs play an integral role in 
regulating vascular medial calcification by initiating vascular smooth muscle transition to 
calcifying vascular cells that express the master osteoblast transcription factors, Runx2 and 
osterix. These osteoblast-like cells also express alkaline phosphatase and elaborate bone 
matrix. Smooth muscle cell transdifferentiation occurs concomitant with the 
downregulation of smooth muscle cell contractile proteins. Calcifying smooth muscle cells 
generate matrix vesicles that contribute to vascular medial calcification by serving as a 
nucleation site for calcium phosphate. These matrix vesicles may also carry miRs that 
regulate phenotype in other cells. miRs also inhibit osteoclastogenesis and likely limit the 
bone resorptive capacity of osteoclast-like cells in the vessel wall to promote vascular 
calcification. This system has significant redundancy, and several miRs target the same 
protein or signaling pathway. 
 
Members of the BMP superfamily are known regulators of calcification, and BMP2 and BMP4 are 
recognized as osteogenic differentiation factors that have been identified in calcified atherosclerotic 
vessels [39]. BMPs activate calcification signaling via a receptor complex (type I and type II Cells 2014, 3   
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receptors) that stimulates Smad 1/5/8 signaling to initiate transcription of Runx2 [15]. BMP2 
stimulates SMC calcification of human coronary artery smooth muscle cells by downregulating the 
expression of miR-30b and miR-30c. These miRs were shown to bind to the 3’-untranslated region of 
Runx2 to regulate its expression. The expression of miR-30b was found to be downregulated in 
calcified human coronary arteries, as well as in calcified stenotic human aortic valves [40,41]. These 
findings are also supported by data from a miR program analysis to determine an miR signature for 
BMP-2-induced osteogenesis in C2C12 mesenchymal cells. This study identified 22 downregulated 
miRs that included miR-133, miR-30 family members and miR-135 that targeted Runx2 and   
Smads [42]. 
It is also known that the wingless-type MMTV integration site family member (Wnt) is required for 
osteoblast function and is involved in SMC transdifferentiation [15]. Wnt/β-catenin signaling is 
activated in calcifying SMCs and is involved in a regulatory circuit that includes miR-29 [16,43]. 
Canonical Wnt signaling was shown to induce miR-29 expression. miR-29, in turn, negatively 
regulates the Wnt inhibitors, Dickkopf, secreted frizzled related protein 2, Kremen and osteonectin, to 
potentiate the calcification phenotype [43,44]. This has been shown in calcifying rat SMCs with 
decreased miR-29 a/b expression and confirmed in calcified aortas from mice and human radial 
arteries harvested from patients with CKD [45]. miR-29 a/b also targets the extracellular matrix 
modulating protein, disintegrin, and metalloproteinase and thrombospondin motifs-7 (ADAMTS-7). 
Transfecting cells with miR-29 mimics inhibited and miR antagomiRs enhanced SMC calcification 
under pro-calcific conditions by modulating ADAMTS-7, BMP-2, p-Smad 1/5/8 and Runx2 protein 
expression [45]. miR-29 was also associated with extracellular matrix remodeling that reduces the 
integrity of collagen and elastin. Therefore, downregulation of miR-29 may also promote vascular 
hypertrophy and fibrosis that facilitates mineralization [46]. 
4. miRs That Regulate Calcium and Phosphate Homeostasis 
Disruptions to calcium and phosphate homeostasis also contribute to SMC transdifferentiation and 
vascular calcification [14]. Studies performed using klotho mutant mice (kl/kl) were analyzed to 
determine the role of miRs in regulating calcium and phosphate handling proteins important for 
vascular calcification. These mice develop precocious vascular calcification with elevated phosphate 
levels and increased vascular Runx2 expression [47]. Using an miR microarray to assess miR 
expression in the aortic media of three-week-old mice, 17 miRs were increased and three miRs were 
decreased (miR-1, miR-93 and miR-302b) in kl/kl mice, as compared to wild-type controls. The levels 
of miR-135a, miR-762, miR-714 and miR-712 were higher in calcified aortas of kl/kl mice as 
compared to wild-type mice, and this expression pattern was confirmed in SMC treated with calcium 
and inorganic phosphate. Bioinformatics revealed that these miRs target the calcium efflux proteins, 
sodium/calcium exchanger NCX1, plasma membrane Ca2+-ATPase-1 and sodium/calcium exchanger 
NCX4. Downregulation of the calcium transporters resulted in an increase in intracellular calcium 
concentrations, which has been implicated in SMC calcification. Interestingly, downregulation or 
upregulation of individual miRs from this group of four had no effect on SMC calcification,   
but inhibiting all four at the same time decreased calcium content by 30%. This led to the conclusion 
that the miRs are specifically involved in calcification and likely function as a cluster; however, this Cells 2014, 3   
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was not proven, and the significance of the other miRs identified in the expression array was not 
examined [48]. 
Studies have also identified miR-223 as an important regulator of vascular calcification in vascular 
SMCs exposed to high levels of inorganic phosphate. miR-223 is expressed in osteoclast precursors, is 
a known mediator of osteoclast phenotype and has been shown to limit RANKL-induced osteoclast 
differentiation. In vitro, miR-223 was upregulated in SMCs under pro-calcific conditions and found to 
promote SMC proliferation and migration, in part by decreasing the expression of its targets, Mef2 and 
RhoB [49–51]. Interestingly, miR-223 was also increased in aortas isolated from murine models of 
chronic kidney disease that are subject to vascular calcification. Here, upregulation of miR-223 was 
associated with downregulation of the transcription factor NFIA and the glucose transporter, GLUT-4, 
at later stages of disease [50,51]. 
To identify other miRs relevant miRs for SMC calcification, murine aorta SMCs grown in 
calcification medium for nine days were studied using miR microarrays. This identified more than 100 
differentially-expressed miRs. Of these, several miRs (miR-221, -222, 24-2, 27a and 31) were confirmed 
to be downregulated in vitro. Further investigation revealed that miR-221 and miR-222 were found to act 
synergistically to induce calcification. Interestingly, these miRs do not target Runx2, but instead 
regulated the expression of ectonucleotide pyrophosphatase/phosphodiesterase 1 and Pit1 to influence 
phosphate metabolism [52]. To date, there are no comprehensive studies using miR microarrays to 
document changing miR profiles over time as SMCs transdifferentiate and mineralize. Studies also 
identified miR-9 as an important regulator of phosphate metabolism. miR-9 functions as a   
negative posttranscriptional regulator and downregulates expression of ectonucleotide 
pyrophosphatase/phosphodiesterase 1, Pit1 and alkaline phosphatase [53]. 
5. miRs That Downregulate the SMC Contractile Phenotype 
In concert with SMC transdifferentiation and the acquisition of an osteoblast-like phenotype, 
calcifying SMCs exhibit downregulation of SMC contractile proteins, such as smooth muscle α-actin 
and smooth muscle myosin heavy chain [14,54]. This phenotype shift involves the miR-143/145 
cluster that regulates the SMC differentiated phenotype, in part by targeting the transcription factor, 
myocardin [42]. Human SMCs exposed to high levels of inorganic phosphate that initiate SMC 
transdifferentiation also exhibit decreased miR-143 and 145 expression. Downregulation of miR-145 
is believed to occur through activation of phosphatidyl inositol-3 kinase/Akt/p53 signaling, leading to 
impaired conversion of pri-miR-145 to pre-miR-145 [55]. Although the decrease in miR-143/145 
expression is not involved directly in the pathogenesis of vascular calcification, there is an indirect 
relationship, as miR-145 targets Krüppel-like factor-4, which mediates high phosphate-induced 
transition of SMCs to osteogenic cells [56]. Other factors known to regulate miR-143/145 expression 
include brg1-containing SWI/SNF complexes that are required for myocardin to induce miR-143/145 
and Notch/Jagged-1 signaling, which increases miR-143/145 in parallel with the serum   
response factor-myocardin complex that binds to CArG sequences to increase miR-143/145 
transcription [57,58]. Therefore, the decreased expression or activity of any of these factors that 
upregulate miR-143/145 would promote the loss of SMC contractile proteins. This is in agreement 
with the finding that circulating miR-145 levels are reduced in patients with atherosclerotic coronary Cells 2014, 3   
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artery disease, a disease that is often associated with vascular calcification [49]. miR-24 also regulates 
SMC contractile marker gene expression. Using high-throughput screening and miRNA libraries, miR-24 
emerged as a master regulator of the SMC phenotype. Increased expression of miR-24 was shown to 
target heme oxygenase-1 and decrease cellular stress resistance, leading to the activation of apoptosis, 
autophagy and the loss of contractile marker genes [59]. 
6. Matrix Vesicles and Circulating miRs 
Transdifferentiated or calcifying SMCs generate extracellular matrix vesicles that serve as mineral 
nucleation sites and have been implicated as an important component of the vascular calcification 
process. These extracellular vesicles are released from SMC in response to elevated intracellular 
calcium levels. The increase in cytosolic calcium initiates translocation of annexin 6 to the plasma 
membrane, which, in turn, signals for the release of the matrix vesicles. These mineralization-
competent vesicles contain noncrystalline calcium and phosphate, as well as other proteins. The initial 
calcium and phosphate ions are packaged as a Ca2+-Pi-phosphatidylserine complex that serves as a 
core to nucleate hydroxyapatite (reviewed in [60]). Prior studies have demonstrated that SMC-derived 
matrix vesicles contain proteins. Mass spectrometry analysis of vesicles has identified at least 79 
proteins that are contained within SMC-derived matrix vesicles. The vesicle proteins are related to 
processes involved in vascular calcification and include proteins that regulate calcification, calcium 
channels and extracellular matrix, matrix and cytoskeletal proteins, oxidant stress-related proteins, as 
well as other serum proteins [61]. Matrix vesicles also contain the calcium-dependent enzyme, 
transglutaminase 2, that crosslinks extracellular matrix and activates matrix metalloproteinase-2 to 
remodel the extracellular matrix and provide sites for mineral deposition [61,62]. 
There is accumulating evidence that matrix vesicles also contain miRs that may importantly 
regulate the phenotype of remote cells or tissues. The SUMOylated protein, heterogeneous nuclear 
ribonucleoprotein A2B1 (hnRNPA2B1), has been shown to bind miRs that contain the motifs GGAG 
and UGCA in the 3’ half of the miR sequence and mark these miRs for packaging in matrix vesicles [63]. 
In fact, several miRs are preferentially packaged in vesicles. RNA-seq analysis identified several miRs 
synthesized by porcine adipose tissue-derived mesenchymal stem cells, including miR148a, miR532-5p, 
miR378 and let-7f, which target genes relevant for apoptosis, angiogenesis, cellular transport and 
proteolysis, that were enriched in matrix vesicles compared to cells [64]. Other studies performed 
using preosteoblast cells identified levels of miR-122-5p, miR-451a, miR-183-5p, miR-144-3p and miR-
142-5p as being ≥10-fold higher in matrix vesicles compared to cells [65]. This observation was 
supported by the finding that there are miRs that are commonly packaged in matrix vesicles across 
several different cell types. Analysis of the matrix vesicles and cellular miR content of HEK293T, 
human microvascular endothelial cells and primary outgrowth endothelial progenitor cells revealed 
that miR-451, miR-150, miR-720, miR-125a, miR-320a and miR-222 were included in the vesicles, 
while miR-10a, miR-26, miR-21, miR-20a, miR-376 and miR-216 were retained by the cells in 
roughly the same proportions in all three cell types [66]. 
It is also recognized that there is a population of circulating miRs in human plasma that are stable 
and independent of matrix vesicles. Thus, there are two populations of miRs in the systemic 
circulation, one that is enclosed in matrix vesicles and one that complexes with Argonaute2 (Ago2), a Cells 2014, 3   
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key component of the RNA-induced silencing complex. miRNA profiling arrays detected 88 plasma 
and 66 serum miRs. Of these, ~15% of the detected circulating miRs were found in eluted fractions 
consistent with matrix vesicles and 66% of plasma and 68% of serum miRs were enriched in fractions 
with Ago2. These findings were validated with select miRs, and similar to other studies, let-7a, miR-
142-3p and miR-150 were identified in matrix vesicles; and miR-122 and miR-150 circulate with 
Ago2 complexes [67]. 
The functional consequences of circulating miRs for the vasculature have been demonstrated and 
provide novel insight into the regulatory function of one cell type over another. For example, 
endothelial matrix vesicles that were generated by cells exposed to shear stress were found to be 
enriched with miR-143 and miR-145. When co-cultured with SMCs, the endothelial-derived vesicles 
containing the miRs were shown to mediate the expression of miR-143/145 target proteins and, 
thereby, phenotype, in SMCs [68]. Others found that shear stress-stimulated endothelial cells secreted 
miR-126 that complexed with Ago2 to decrease forkhead box O3, insulin receptor substrate 1 and  
B-cell lymphoma 2 mRNA in the SMCs [69]. 
These functional interactions become important, as there are a few reports of associations between 
circulating miRs and vascular calcification in patients with chronic kidney disease (CKD) or coronary 
artery disease. In 90 patients with CKD Stage 3-4, circulating levels of miR-125b, miR-145 and   
miR-155, which target Runx2, the angiotensin type 1 receptor and myocardin, were decreased 
compared to levels measured in healthy volunteers, and the decrease in these miRs was concordant 
with the decline in the glomerular filtration rate [70]. Other investigators found decreased levels of 
miR-15b, which has targets involved in phosphate metabolism, in 30 CKD patients compared with 20 
healthy controls. In this study, circulating miR-15b was found to correlate positively with estimated 
glomerular filtration rate (r = 0.502, p = 0.003) and negatively with phosphate levels (r = −0.516, p = 
0.004) [71]. 
One study reviewed existing literature to identify circulating miRs common to CKD, CAD and 
diabetes mellitus, all diseases that have a high prevalence of vascular calcification. In this analysis, 
which included 15 studies, seven miRs were found to be common to at least two of the three diseases 
(miR-21, miR-27, miR-34a, miR-126, miR-146a, miR-155 and miR-210). miR-21 was the only miR 
that was found to be common among all of the diseases, which is not surprising, as miR-21 targets 
BMPR2 and is, therefore, likely involved in the calcification process. Interestingly, when miR-21 
levels were measured in the serum and calcified atherosclerotic and peripheral arterial disease vessels, 
they were elevated in the vessels and decreased in serum. This may be explained, in part, by the timing 
of measurements relative to calcification, as well as the concept that serum levels may have been 
depleted after the delivery of miR-21 to the vessels [72]. Although the aforementioned studies provide 
some early insight into the relationship between circulating miRs and vascular calcification, more 
definitive information will be obtained with the completion of the MAP-Calcification Study 
(ClinicalTrials.gov: NCT01992848). This study will enroll 100 patients using a case-control study 
design to identify miRs as putative biomarkers for coronary calcification. 
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7. miRs and Osteoclastogenesis 
Another theory of vascular calcification posits that, similar to bone formation, which is a dynamic 
process that involves simultaneous bone matrix elaboration by osteoblasts and resorption by 
osteoclasts, the osteoclast-like cells are deficient in either number or activity [14]. The contribution of 
osteoclastogenesis and osteoclast-like cells to vascular calcification remains somewhat controversial; 
however, the finding of osteoclast-like cells in calcified areas of vessel indicates that this is likely to be 
a significant component of the vascular calcification process [39]. The integrated nature of bone 
formation and resorption has been described in studies performed in Runx2 knockout mice. These 
mice have a complete lack of normal bone formation that is characterized by an absence of osteoclasts, 
suggesting that Runx2 regulates the expression of a factor necessary for osteoclast formation [73]. 
While levels of the osteoclast inhibitory factor, osteoprotegerin, were found to be normal, the levels of 
the receptor activator of nuclear factor-kappaβ ligand (RANKL), which promotes osteoclast 
differentiation, were diminished. Using a Runx2 null calvaria-derived cell line (CA120-4), osteoclast 
differentiation from normal bone marrow cells in co-culture was decreased significantly in the absence 
of Runx2. Confirmatory studies performed using adenovirus-mediated gene transfer of Runx2 further 
demonstrated normal osteoclast differentiation from bone marrow cells, indicating that Runx2 
promotes osteoclast differentiation by inducing RANKL and inhibiting osteoprotegerin [74]. 
The link between calcifying vascular SMCs and osteoclast-like cells has also been examined. In 
vitro  studies confirmed that once SMC transdifferentiated to osteoblast-like cells and expressed 
Runx2, Runx2 increased the expression and secretion of RANKL by binding directly to the RANKL 
promoter. This, in turn, resulted in the migration and differentiation of bone marrow-derived macrophages. 
These bone marrow-derived macrophages transitioned into multinucleated tartrate-resistant acid 
phosphatase-positive functional osteoclast-like cells. The obligate role of Runx2 was confirmed by 
performing similar in vitro studies with Runx2 null SMC with diminished RANKL expression [75]. 
Subsequent in vivo studies using a high-fat diet as the stimulus to induce vascular calcification 
revealed that SMC-Runx2-deficient mice had decreased vessel mineralization, and this finding was 
accompanied by a decrease in RANKL, as well as limited vascular macrophage infiltration and 
formation of osteoclast-like cells. Thus, vascular calcification is coupled to the formation of osteoclast-
like cells, similar to what is observed for skeletal bone formation [76]. 
The role of miRs in regulating osteoclastogenesis was defined by examining osteoclast precursors 
with a global deletion of the miR processing factors, Dgcr8, Dicer or Ago2. The consequence of 
inhibiting global miR expression was that osteoclast differentiation was prevented owing to a decrease 
in the osteoclast transcription factors, PU.1, Mitf, fos and Nfatc1 [77]. Studies performed in mice with 
Dgcr8 deficiency confirmed this phenomenon by demonstrating impaired osteoclast function, which 
resulted in an increase in bone mass [78]. 
Although there have been no studies that have directly examined the role of miRs in regulating the 
differentiation of monocytes/macrophages to osteoclast-like cells in calcifying vessels, it is highly 
plausible that the same miRs that regulate osteoclast function are operative in vascular calcification 
(Figure 1). This speculation is supported by the fact that there are several miRs that have been linked 
to both osteoclastogenesis, as well as cardiovascular disease. In particular, miR-126, which targets 
RANKL, is decreased in patients with diabetes mellitus and coronary artery disease, who have a high Cells 2014, 3   
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prevalence of vascular calcification [79,80]. Similarly, miR-146a, which is expressed in atherosclerotic 
arteries, inhibits osteoclastogenesis by limiting the number of tartrate-resistant acid phosphatase   
positive cells [81,82]. 
It is notable that miR-34a, which is related to the Runx2-targeting miR-34c, has been identified as a 
potent inhibitor of osteoclastogenesis. miR-34a knockdown mice had evidence of increased bone 
resorption and decreased bone mass, while transgenic miR-34 mice exhibited the opposite effect. 
Studies found that miR-34 targeted the pro-osteoclastogenic factor transforming growth factor-β-induced 
factor 2 (Tgif2). In vivo studies identified an important regulatory role for miR-34 by demonstrating 
that it was involved in osteoporosis and cancer-related bone metastasis [83]. Similarly, miR-29b, 
which mediates Wnt signaling in calcifying SMC is decreased progressively in human osteoclasts 
during osteoclastogenesis. Overexpression of miR-29 confirmed that it regulates osteoclastogenesis by 
targeting Nfatc1, cathepsin K, matrix metalloproteinase-9, tartrate resistant acid phosphatase and 
RANK expression, leading to a decrease in bone resorption activity and extracellular matrix 
degradation [84]. In contrast, studies performed in mice showed that miR-29b is upregulated in bone 
marrow-derived cells during osteoclastogenesis, suggesting that osteoclast-regulating miRs may have 
different functions in different cell types [85].  
Other miRs have also been implicated in the regulation of osteoclast function. In postmenopausal 
women with osteoporosis and increased osteoclast activity, miR-503 was downregulated in CD14+ 
peripheral blood mononuclear cells. In vitro analysis confirmed that miR-503 targeted the osteoclast 
receptor RANK and was regulated by 17 β-estradiol [57]. Thus, it is likely that miR-503 is upregulated 
in vascular calcification, where osteoclastogenesis is deficient. Similarly, miR-148a was identified as a 
highly upregulated miR in peripheral blood mononuclear cells and found to target V-maf 
musculoaponeurotic fibrosarcoma oncogene homolog B (Mafb), a negative regulator of 
osteoclastogenesis [86]. miR-125a was also found to be downregulated during osteoclastogenesis in 
peripheral blood mononuclear cells. Downregulation of this miR led to upregulation of its direct target 
tumor necrosis factor receptor associated factor 6, which is essential for normal osteoclast function. In 
addition, the osteoclast transcription factor Nfatc1 was shown to bind to the miR-125a promoter and 
inhibit its transcription, thereby identifying a feedback loop [87]. Taken together, there is compelling 
evidence to indicate that miRs govern osteoclast maturation and function and that these findings can be 
extrapolated to vascular calcification. 
8. Conclusions 
Vascular calcification is a severe vascular end pathophenotype that is associated with vascular 
dysfunction and is not reversible. Vascular medial calcification, in particular, may occur in the absence 
of atherosclerosis and is prevalent in diabetes mellitus, CKD and with aging. The processes that 
govern vascular medial calcification are incompletely understood, but include transdifferentiation of 
SMC to osteoblast-like cells, release of circulating matrix vesicles containing calcium phosphate that 
serve as nucleation sites for calcification and a decreased number or activity of osteoclast-like cells 
that resorb bone matrix. Each of these pathophysiological processes involves genetic reprogramming 
that is regulated by miRs. Changes in miR expression have been shown to mediate SMC and monocyte 
acquisition of an osteoblast- or osteoclast-like phenotype, respectively. Moreover, the finding of Cells 2014, 3   
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several unique miRs, as well as several common miRs is indicative of redundancy in the system. It is 
likely that these miRs are able to regulate phenotype shifts via distinctive miR programs with temporal 
and cell-specific signatures that initiate SMC calcification. Future studies that identify these programs 
will identify master regulatory miRs that are amenable to therapeutic intervention. 
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